To describe a case of neoehrlichiosis, an emerging opportunistic tick-borne infection, in a patient with multiple sclerosis (MS) treated with ocrelizumab.
Methods:
This is a case study.
Results:
Our patient developed clinical infection over several months while on ocrelizumab and was ultimately diagnosed with neoehrlichiosis, caused by the bacteria Neoehrlichia mikurensis. Resolution of symptoms began within a few days after the initiation of antibiotic treatment.
Conclusion:
We describe the first probable case of ocrelizumab-associated neoehrlichiosis in a patient with MS. Clinicians should be aware of this potentially debilitating and life-threatening infection in patients receiving CD20-depleting therapy.
de SèzeJMaillartEGueguenA, et al. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Front Immunol2023; 14: 1004795.
2.
JuanateyABlanco-GarciaLTellezN. Ocrelizumab: Its efficacy and safety in multiple sclerosis. Rev Neurol2018; 66(12): 423–433.
3.
Welinder-OlssonCKjellinEVahtK, et al. First case of human “Candidatus Neoehrlichia mikurensis” infection in a febrile patient with chronic lymphocytic leukemia. J Clin Microbiol2010; 48(5): 1956–1959.
4.
DadgarAGrankvistAWernbroL, et al. Fever of unknown origin in a multiple sclerosis patient on immunomodulatory therapy was due to neoehrlichiosis. Lakartidningen2017; 114: EM6L.
5.
HöperLSkoogEStensonM, et al. Vasculitis due to Candidatus Neoehrlichia mikurensis: A cohort study of 40 Swedish patients. Clin Infect Dis2021; 73(7): e2372–e2378.
6.
GynthersenRMMStensvoldCRNielsenSL, et al. Neoehrlichia mikurensis—An emerging opportunistic tick-borne infection in immunosuppressed patients. J Intern Med2023; 293(6): 782–790.
7.
GrankvistAAnderssonPOMattssonM, et al. Infections with the tick-borne bacterium “Candidatus Neoehrlichia mikurensis” mimic noninfectious conditions in patients with B cell malignancies or autoimmune diseases. Clin Infect Dis2014; 58(12): 1716–1722.
8.
WenneråsC. Infections with the tick-borne bacterium Candidatus Neoehrlichia mikurensis. Clin Microbiol Infect2015; 21(7): 621–630.
9.
PorskrogAHimmelstrupBM. Flatbaren Candidatus Neoehrlichia mikurensis var arsag til feber hos en haematologisk patient. Ugeskr Læger2020; 182: V05200387.
10.
PortilloASantibáñezPPalomarAM, et al. “Candidatus Neoehrlichia mikurensis” in Europe. New Microbes New Infect2018; 22: 30–36.
11.
BoyerPHBaldingerLDegeilhB, et al. The emerging tick-borne pathogen Neoehrlichia mikurensis: First French case series and vector epidemiology. Emerg Microbes Infect2021; 10(1): 1731–1738.
12.
MachlańskaAHelbigGChromikK, et al. Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis. Mult Scler2021; 27(11): 1803–1805.
13.
OšepABBreclEŠkergetM, et al. An unforeseen reality: Hemophagocytic lymphohistiocytosis following alemtuzumab treatment for a multiple sclerosis. Clin Neurol Neurosurg2023; 228: 107675.
